Golfyeti - I remember reading the article(s) you are referring to maybe in 2015 or 16 and had something to do with a Swedish study.

Its kind of funny that iconoclast has more comfort in ABL having more comfort in CVD and CKD where from what I have read I have more confidence in its prospects to positively affect dementia.

I guess that's what makes a market.

Of course hitting on all three would be most desirable.

tada